494 related articles for article (PubMed ID: 27775669)
21. [Aberrant micro RNA and epigenetic network are associated with progression from MGUS to multiple myeloma].
Handa H
Rinsho Ketsueki; 2015 Aug; 56(8):981-8. PubMed ID: 26345556
[TBL] [Abstract][Full Text] [Related]
22. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
23. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
24. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
Schinke C; Qu P; Mehdi SJ; Hoering A; Epstein J; Johnson SK; van Rhee F; Zangari M; Thanendrarajan S; Barlogie B; Davies FE; Yaccoby S; Morgan GJ
Clin Cancer Res; 2018 Jun; 24(12):2913-2919. PubMed ID: 29563136
[No Abstract] [Full Text] [Related]
25. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.
Awada H; Thapa B; Awada H; Dong J; Gurnari C; Hari P; Dhakal B
Cells; 2021 Aug; 10(8):. PubMed ID: 34440730
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.
Thomsen H; Chattopadhyay S; Weinhold N; Vodicka P; Vodickova L; Hoffmann P; Nöthen MM; Jöckel KH; Langer C; Hajek R; Hallmans G; Pettersson-Kymmer U; Ohlsson C; Späth F; Houlston R; Goldschmidt H; Hemminki K; Försti A
Leukemia; 2019 Jul; 33(7):1817-1821. PubMed ID: 30737484
[No Abstract] [Full Text] [Related]
28. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
[TBL] [Abstract][Full Text] [Related]
29. Established and Novel Prognostic Biomarkers in Multiple Myeloma.
Bustoros M; Mouhieddine TH; Detappe A; Ghobrial IM
Am Soc Clin Oncol Educ Book; 2017; 37():548-560. PubMed ID: 28561668
[TBL] [Abstract][Full Text] [Related]
30. FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma.
Korać P; Peran I; Skrtić A; Ajduković R; Kristo DR; Dominis M
Pathol Int; 2009 May; 59(5):354-8. PubMed ID: 19432679
[TBL] [Abstract][Full Text] [Related]
31. Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation.
Takagi S; Tsukamoto S; Park J; Johnson KE; Kawano Y; Moschetta M; Liu CJ; Mishima Y; Kokubun K; Manier S; Salem KZ; Huynh D; Sacco A; Forward J; Roccaro AM; Battinelli EM; Ghobrial IM
Clin Cancer Res; 2018 May; 24(10):2430-2439. PubMed ID: 29440174
[No Abstract] [Full Text] [Related]
32. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
33. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathogenesis of multiple myeloma.
Tonon G
Hematol Oncol Clin North Am; 2007 Dec; 21(6):985-1006, vii. PubMed ID: 17996585
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors.
Salhia B; Baker A; Ahmann G; Auclair D; Fonseca R; Carpten J
Cancer Res; 2010 Sep; 70(17):6934-44. PubMed ID: 20736376
[TBL] [Abstract][Full Text] [Related]
36. [Pathogenesis of multiple myeloma].
Rasche L; Weinhold N
Internist (Berl); 2019 Jan; 60(1):3-9. PubMed ID: 30536029
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms in multiple myeloma drug resistance.
Nikesitch N; Ling SC
J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma: a model for scientific and clinical progress.
San Miguel J
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):1-7. PubMed ID: 25696828
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathogenesis of multiple myeloma and its premalignant precursor.
Kuehl WM; Bergsagel PL
J Clin Invest; 2012 Oct; 122(10):3456-63. PubMed ID: 23023717
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathogenesis of multiple myeloma.
Furukawa Y; Kikuchi J
Int J Clin Oncol; 2015 Jun; 20(3):413-22. PubMed ID: 25953678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
